Full-Time

Medical Laboratory Scientist

Medical Laboratory Scientist, Blood Bank

Tenet Healthcare

Tenet Healthcare

10,001+ employees

Operates hospitals and clinics; revenue cycle

No salary listed

Detroit, MI, USA

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)

Get referred to Tenet Healthcare

See people who can refer or advise you

Requirements
  • A Bachelor's Degree from an approved college or university, graduation from an accredited school of medical technology, equivalent military training, or qualification at the Medical Technologist level through the specified HHS examination pathway.
  • The education and qualification must meet Clinical Laboratory Improvement Amendments requirements for high-complexity testing under 42 CFR 493.1489 and 42 CFR 493.1491.
  • Registration or registry eligibility with an approved certifying agency such as the American Society for Clinical Pathology, National Certification Agency, American Medical Technologists, or Canadian Society for Medical Laboratory Science within 12 months of hire.
  • For non-US-trained personnel, completion of an equivalency evaluation by Educational Credential Evaluators, National Association of Credential Evaluation Services, or Association of International Credential Evaluators within 30 days of hire.
  • State licensure, when required.
  • Analytical ability to interpret and analyze test results.
  • Interpersonal skills to work effectively with all areas of the physician office.
  • Manual dexterity and visual acuity to operate various types of laboratory equipment.
  • Visual acuity to closely examine specimens.
Responsibilities
  • Perform quantitative and qualitative laboratory tests on patient specimens according to standard laboratory formulas and procedures.
  • Analyze test results and prepare samples for testing.
  • Calculate test findings and maintain records.
  • Prepare solutions, reagents, media, stains, and other materials used in the testing process and determine their validity.
  • Process and test all types of laboratory specimens.
  • Review and report laboratory results.
  • Perform operational duties, maintenance, and advanced troubleshooting of laboratory instrumentation and equipment.
  • Act as a resource to other laboratory personnel.
Desired Qualifications
  • Six months to one year of medical laboratory technologist or clinical laboratory scientist experience in an acute care facility.

Tenet Healthcare operates a large network of hospitals and outpatient facilities across the United States, including 65 hospitals and about 500 other centers such as surgical hospitals, urgent care sites, and imaging centers. It also owns Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients, helping them manage billing and payments and improve patient outcomes. The company earns revenue mainly from patient services and from Conifer’s administrative and financial services. Its goal is to deliver the right care, in the right place, at the right time, while improving patient outcomes and operational efficiency and serving as a trusted employer and partner.

Company Size

10,001+

Company Stage

IPO

Headquarters

Dallas, Texas

Founded

1967

Get referred to Tenet Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 EPS hit $6.12; management raised 2026 EPS guidance to $20.30-$21.69.
  • Tenet authorized another $2 billion buyback in July 2026 after repurchasing $1.04 billion.
  • USPI bought seven ASCs in Q1 2026 and opened three centers, expanding high-acuity growth.

What critics are saying

  • Florida federal injunction on March 6, 2026 escalates courtroom risk for Tenet hospitals.
  • Hospital reimbursement pressure and weak utilization can compress margins if patient mix deteriorates in 2026.
  • Heavy leverage and buyback dependence create an existential shock risk if earnings normalize sharply.

What makes Tenet Healthcare unique

  • USPI’s 570+ ASCs monetize outpatient migration with 39.0% Q2 2026 EBITDA margins.
  • Tenet paired hospitals and ambulatory centers, lifting Q2 2026 revenue to $5.63 billion.
  • Conifer revenue-cycle services deepen payer, billing, and data control across provider customers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Mental Health Support

Paid Sick Leave

Paid Holidays

Paid Vacation

Health Insurance

Flexible Work Hours

Company News

Kalkine
Aug 12th, 2026
Tenet Healthcare (NYSE: THC)'s stock climbs 30.1% year-to-date to $259.45 amid turnaround efforts.

Tenet Healthcare (NYSE: THC)'s stock climbs 30.1% year-to-date to $259.45 amid turnaround efforts. 12 August 2026 11:30 AM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Tenet Healthcare's stock has climbed to $259.45, reflecting a substantial 30.1% gain year-to-date. This recovery signals successful turnaround strategies, making the company an appealing prospect for investors looking for growth in the healthcare sector. Key Highlights * Tenet Healthcare Corp (NYSE: THC). * Tenet Healthcare's recent performance illustrates a successful recovery strategy. * Investors are taking note of Tenet Healthcare's significant year-to-date gain and the implications for its Long-term Growth prospects. Tenet Healthcare Corp (NYSE: THC). has seen its stock price stabilize at $259.45, marking a significant 30.1% appreciation this year as the company pushes its growth initiatives. Investors are encouraged by this upward trend after the stock had fluctuated within a 52-week range of $157.58 to $265.32. With a market cap of $20.9 billion, Tenet demonstrates resilience, capturing investor interest amid rising operational efficiency and strategic market repositioning. The healthcare provider's ongoing turnaround efforts appear to resonate well with the market. What Happened Tenet Healthcare's recent performance illustrates a successful recovery strategy. The company reported strong operational efficiency and a noticeable improvement in its service delivery model. The stock has appreciated 33.2% over the last month, indicating heightened investor confidence in the healthcare provider's trajectory. This timely recovery aligns with a broader trend of increasing acceptance of elective procedures, which Tenet capitalizes on through its extensive network of hospitals and ambulatory care centers. As a result, its stock performance stands out in a notoriously volatile healthcare sector, making it a focal point for investors. Implications Investors are taking note of Tenet Healthcare's significant year-to-date gain and the implications for its long-term growth prospects. Tenet's strategic initiatives, including its investments in free-standing emergency departments and outpatient facilities, position the company favorably against sector peers. The operational improvements and enhanced service offerings may drive stronger Revenue growth, important for maintaining this upward momentum. Comparatively, Tenet's closest competitors, EHC and UHS, have shown less impressive stock movements, which could suggest a competitive edge for Tenet. The company's continued focus on operational excellence could elevate investor sentiment further. What's Next Looking ahead, Tenet Healthcare is expected to face challenges as it strives to sustain its growth momentum. The upcoming quarterly Earnings report will be key, providing insights into how effectively the company can Capitalize on recent gains. Analysts will scrutinize metrics related to patient volumes, service mix, and revenue generation strategies, all of which play a critical role in the company's financial health. As the company navigates potential external challenges like regulatory pressures and market competition, its performance in upcoming reports will be important to maintaining investor confidence. Peers Moving on This News * Encompass Health Corp (NYSE: EHC) little changed * Universal Health Services Inc (NYSE: UHS) down 0.3% FAQs. Q: How has Tenet Healthcare's stock performed recently? A: Tenet Healthcare's shares have risen to $259.45, reflecting a strong 30.1% increase year-to-date, showcasing effective turnaround strategies that attract investors seeking growth. Q: What does Tenet's recent share performance indicate for future growth? A: Tenet's 33.2% increase over the past month suggests positive sentiment surrounding its operational efficiency and service offerings, positioning the company well against competitors in the healthcare market. Q: What are the key factors impacting Tenet Healthcare's stock valuation? A: Key factors include operational improvements, patient volume trends, and strategic investments in outpatient facilities, which significantly influence revenue generation and overall stock performance. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

ClickOnDetroit
Aug 6th, 2026
Karmanos files lawsuit against DMC amid rising costs, service threats.

Karmanos files lawsuit against DMC amid rising costs, service threats. The services include laboratory operations, operating room access, scheduling, IT integration, and dietary services. Keep Watching DETROIT - Karmanos Cancer Hospital has filed a lawsuit against Detroit Medical Center and its parent company, Tenet Healthcare, alleging the for-profit health system threatened to cut critical services - a move Karmanos says could jeopardize care for thousands of cancer patients. "We did not arrive at this conclusion or this action lightly," said Brian Gamble, president and CEO of Karmanos Cancer Hospital. The services include laboratory operations, operating room access, scheduling, IT integration and dietary services. "We took this action as a preemptive action to preserve and protect our patients," Gamble said. Background: Karmanos, DMC separate but remain tied. The dispute has roots in a 2005 agreement signed when Karmanos separated from DMC and became Michigan's only independent, freestanding cancer hospital. Under that agreement, Karmanos leases space on DMC's downtown Detroit campus and is required to purchase certain services through DMC. Karmanos says the relationship has grown increasingly strained - citing rising costs and declining service quality. "We are lacking transparency, and we are not satisfied with the solutions and the service levels we are getting," Gamble said. From $28M to $82M: Costs at the center of the dispute. At the heart of the lawsuit is a dramatic increase in service fees. According to the filing, Tenet was charging Karmanos approximately $28 million annually for services. Karmanos alleges Tenet is now seeking $82 million. Karmanos also claims that although it accounts for only 25-30% of operating room utilization, DMC allocates approximately 75% of related costs to the center. The lawsuit states multiple requests for an explanation have gone unanswered. What this means for patients. For now, services have not been disrupted as a judge weighs both sides of the dispute. "Despite our contractual disagreements with Tenet and DMC, there will be no disruption to patient care," Gamble said. Karmanos is one of fewer than 60 National Cancer Institute-designated Comprehensive Cancer Centers in the country and the only one in metro Detroit. The center treated nearly 16,000 new cases in fiscal year 2025 - the most in its history. The lawsuit argues that financial resources that could support enhanced patient care have instead been directed toward payments to DMC, and that DMC has repeatedly blocked Karmanos' efforts to expand and build new facilities. "Bottom line - we're fighting for the future of cancer care in Detroit and our region," Gamble said. "This is about protecting patients, supporting our teams and ensuring Karmanos can continue to grow to improve the quality of service provided and invest and serve the community for generations to come." DMC and Tenet Healthcare have not yet issued a public statement regarding the allegations at the time of this report. "For more than 100 years, the Detroit Medical Center has been this city's healthcare safety net. Thousands of patients are being seen and treated on our campus every day. Karmanos is owned by McLaren Health Care, headquartered in Grand Blanc, and has no other presence in our city, preferring to center their broader healthcare services in wealthier suburbs of Michigan while relying on the DMC to subsidize its operations locally. Karmanos was built here, on DMC's campus, with DMC, for Detroit's patients. DMC supplies to Karmanos what a cancer hospital cannot run without: laboratory, medical records, and operating room services among others. McLaren made a long term commitment with Karmanos in Detroit and now files a frivolous lawsuit as a disguised attempt to renege on their commitments on the DMC campus. For more than a year, McLaren decided on its own what to pay for the support services it uses every day and paid a fraction of the cost. McLaren, as one of the wealthiest hospital systems in America that also owns an insurance company spent over a year asking a Detroit safety-net hospital to subsidize it. We absorbed the loss rather than let a payment dispute reach a single bedside. When finally asked to pay fair market value, McLaren sued, skipping the private mediation its own agreements require. That was a choice about publicity, and not about principle. DMC honored its agreements. To this day, despite subsidizing the cost of these services for Karmanos, all necessary care remains available from the DMC. We expect McLaren to honor its own commitments. We reject the allegations and will answer them in court. We will not be taken advantage of. Not when the people of Detroit are the ones who pay for it. Detroit Medical Center

StocksToTrade
Jul 25th, 2026
Tenet Healthcare stock surges after blockbuster Q2 beat.

Tenet Healthcare stock surges after blockbuster Q2 beat. TIM BOHEN - UPDATED JUL. 25, 2026, 8:37 AM ET Tenet Healthcare Corporation stocks have been trading up by 17.17 percent, driven mainly by strong earnings and upbeat guidance. What traders need to know. * Q2 2026 adjusted EPS came in at $6.12 versus $4.26 consensus on $5.63B revenue, powered by strong same-store growth, tight cost control, and higher-acuity services. * Management lifted 2026 guidance to adjusted EPS of $20.30-$21.69 and revenue of $21.9B-$22.5B, with about $295M more EBITDA and $225M more free cash flow at the midpoint. * Share repurchase capacity increased by $2B after $1.04B bought back last quarter, leaving $2.13B available and targeting roughly a 6% reduction in share count at current prices. * The stock ripped more than 16-17% after the earnings release and guidance hike, strongly separating itself from a mostly flat healthcare tape. * Major banks including BofA, Barclays, Wells Fargo, UBS, and Guggenheim all stay positive on THC, with targets clustered roughly in the $231-$290 range. Weekly Update Jul 20 - Jul 24, 2026: On Saturday, July 25, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 17.17%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Healthcare industry expert: Analyst sentiment - positive Tenet Healthcare (THC) is operating as a top-tier acute-care and ambulatory consolidator with sector-leading profitability: EBIT margin 18.6%, EBITDA margin 22.8%, and consolidated net margin 7.9% on $21.3B revenue, all above typical hospital peers. Returns on equity (38-49%) and capital (10-25%) are exceptional, powered by strong asset turnover and mix shift to higher-acuity and ASC volumes. Leverage is elevated (total debt/equity 2.7x; LT debt/cap ~73%) but comfortably serviced (interest coverage 5.9x) and supported by $1.46B quarterly FCF, modest capex, and aggressive buybacks at a single-digit P/E (~9x) and 0.7x sales. The stock's weekly tape shows a powerful breakout and follow-through: from ~195 to a spike high near 233, closing at 233.2, confirming a vertical expansion in range with clear institutional demand. Intraday 5-minute candles post-earnings show repeated high-volume buying above 220 and shallow pullbacks, indicating strong dip support rather than distribution. Dominant trend is firmly bullish. A key actionable level is $220: use it as primary support and stop zone for swing longs, with fresh entries on low-volume pullbacks toward 225-228 targeting continuation above recent highs. Fundamentals, revisions, and positioning place Tenet ahead of both the Healthcare sector and Healthcare Providers & Services peers on growth, margins, and FCF conversion. Q2 results massively beat expectations, guidance for 2026 EPS and EBITDA moved materially above Street, and multiple banks raised targets into the $270-290 range as shares jumped >15%. Expanded $2B buyback plus $2.13B remaining capacity adds structural support. I see upside toward $275-285 over 12 months, with key support at $220 and interim resistance near $250. Quick financial overview. Tenet Healthcare Corporation (THC) just printed the kind of quarter that resets expectations. Q2 2026 adjusted EPS of $6.12 not only smashed the $4.26 consensus, it also marked a sharp jump from last year's $4.02. Revenue of $5.63B beat estimates and was backed by higher same-facility revenue and better hospital margins, not just accounting noise. For traders, that matters: strong price and volume in the business usually supports strong price and volume in the stock. The guidance move is just as important. THC now sees 2026 adjusted EPS at $20.30-$21.69 and revenue at $21.9B-$22.5B, with about $295M more adjusted EBITDA and $225M more free cash flow at the midpoint. Key ratios back up this earnings power: EBIT margin sits around 18.6%, EBITDA margin roughly 22.8%, and return on equity is very high near 48.5%. The balance sheet is still leveraged with total debt-to-equity at 2.74, but interest coverage of 5.9 and free cash flow of about $1.46B for the recent quarter help support that load. On valuation, THC trades around a 9.2 P/E and about 0.7 times sales, with price-to-free-cash-flow near 2.5, which is low for a name delivering this type of growth. The chart confirms that traders are re-rating the stock. Weekly data show a breakout from the high-$190s into the low-$230s, with a huge expansion in the range once earnings hit: a move from roughly $199 to a spike near $233-$235 in just days, and an intraday high around $246 on the post-earnings session before closing near $233. That kind of wide intraday bar after a gap up usually signals heavy participation and sets up a new trading range for the coming weeks. Conclusion. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. 2x opportunities. Every Monday. Every week on Monday morning... I've been targeting gains up to 149% before lunch. Yes - 2x opportunities. Every Monday. I call it the Money Monday trade... And if you get it right, it could set you up for the whole week!

Yahoo Finance
Jul 24th, 2026
Tenet Healthcare shares jump 15% as Q2 earnings beat forecasts and full-year guidance raised to $20.30–$21.69 per share

Tenet Healthcare shares surged 14.6% in premarket trading on Friday after the Dallas-based hospital operator delivered stronger-than-expected second-quarter results and raised its full-year outlook. The company reported earnings of $6.12 per share, well above the $4.26 consensus estimate. Revenue reached $5.63 billion, exceeding expectations of $5.43 billion. Tenet also substantially increased its 2026 guidance, now expecting earnings per share between $20.30 and $21.69, ahead of the previous consensus of $17.81. Revenue guidance was lifted to between $21.9 billion and $22.5 billion. The results come as investors have grown cautious toward hospital operators. Earlier this earnings season, HCA Healthcare lowered its full-year profit outlook after reporting pressure from unfavourable payer mix.

Market Chameleon
Jul 24th, 2026
Tenet Healthcare lifts 2026 outlook as EBITDA jumps, margins strengthen across segments.

Tenet Healthcare lifts 2026 outlook as EBITDA jumps, margins strengthen across segments. 24 July 2026, 11:07 AM Q2 EBITDA exceeds expectations; outlook raised on back of broad-based growth. Tenet Healthcare (NYSE: THC) delivered a strong second quarter for 2026, reporting a consolidated adjusted EBITDA of $1.30 billion - up 16.3% over last year - and pushing margins to 23.2%. Management's improved 2026 outlook now calls for consolidated adjusted EBITDA in the range of $4.83-$5.03 billion, a $295 million increase at the midpoint. Adjusted free cash flow guidance also rose, now expected between $2.73-$3.03 billion for the year. These numbers not only surpassed prior internal targets but also pointed to broad operational strength as both the hospital and ambulatory segments showed material improvement. Margin expansion and segment details highlight management's execution. Tenet's improved profitability was visible across its two main segments. The hospital segment's EBITDA margin rose to 18.0% from 15.6% in the prior year, aided by strong growth in same-facility revenue and disciplined expense management. Ambulatory care margins remained industry-leading at 39.0%, as operational leverage offset slight softness in surgical case volumes. Management noted that strategic investments in high-acuity services and innovation continue to drive this margin expansion despite payer mix headwinds. | Segment | Q2 2026 Adjusted EBITDA ($M) | Q2 2026 EBITDA Margin (%) | YoY EBITDA Growth (%) | | Ambulatory Care | 542 | 39.0 | 8.8 | | Hospital Operations & Services | 762 | 18.0 | 22.3 | | Total | 1,304 | 23.2 | 16.3 | Shareholder returns accelerate with $2 billion share repurchase boost. In addition to robust financials, Tenet's board authorized a $2.0 billion expansion of its share buyback program, bringing the total authorization to $2.13 billion as of late July 2026. The company repurchased $1.36 billion in shares over the first six months of the year, reflecting the management's confidence in Tenet's long-term trajectory and strong cash generation. Tenet's net debt to adjusted EBITDA was 2.33x at quarter-end, remaining at a manageable level. Operating trends support upbeat guidance. Both segments delivered healthy top-line growth: ambulatory net revenues grew 9.3% year-over-year, driven by higher net revenue per case (+6.3%) and continued expansion in service lines. Hospitals benefited from improved admissions (+2.3%) and disciplined cost control despite some pressured payer mix. The company's full-year forecast expects further gains in net operating revenue, higher adjusted EBITDA margins (22.1-22.4%), and solid cash flows to support ongoing investments and capital returns. | Key Outlook Metrics (FY 2026) | Updated Range ($B) | Prior Midpoint ($B) | Change ($M) | | Adjusted EBITDA | 4.83 - 5.03 | 4.635 | +295 | | Adjusted Free Cash Flow | 2.73 - 3.03 | 2.8 | +225 | Key takeaways: operational discipline and strategic focus drive upside. Tenet Healthcare's strong second quarter and raised 2026 outlook point to successful execution of its growth and efficiency strategy. Margin improvements across both hospital and ambulatory segments highlight a focus on service mix, cost management, and investments in higher-acuity care. With balance sheet flexibility and an enhanced buyback program, Tenet appears well-positioned to capitalize on evolving industry dynamics in the coming quarters. Investors may want to monitor further updates on capital deployment and margin stability as management continues its webcast discussion and publishes additional materials on its investor relations site. Contact Information: If you have feedback or concerns about the content, please feel free to reach out to Market Chameleon via email at [email protected]. About the Publisher - Marketchameleon.com: Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. Market Chameleon leverage extensive data, models, and analytics to provide valuable insights into these markets. Its primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards. NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com. The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information. Disclosure: This article was generated with the assistance of AI